WO2017210148A1 - Compositions and methods for self-recombination plasmid transformation - Google Patents
Compositions and methods for self-recombination plasmid transformation Download PDFInfo
- Publication number
- WO2017210148A1 WO2017210148A1 PCT/US2017/034917 US2017034917W WO2017210148A1 WO 2017210148 A1 WO2017210148 A1 WO 2017210148A1 US 2017034917 W US2017034917 W US 2017034917W WO 2017210148 A1 WO2017210148 A1 WO 2017210148A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- acid sequence
- restriction enzyme
- selectable marker
- vector
- Prior art date
Links
- 239000013612 plasmid Substances 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 40
- 230000009466 transformation Effects 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title abstract description 5
- 238000005215 recombination Methods 0.000 title description 7
- 239000003550 marker Substances 0.000 claims abstract description 81
- 108091081024 Start codon Proteins 0.000 claims abstract description 32
- 238000002744 homologous recombination Methods 0.000 claims abstract description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 140
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 98
- 108091008146 restriction endonucleases Proteins 0.000 claims description 63
- 210000004027 cell Anatomy 0.000 claims description 47
- 102000039446 nucleic acids Human genes 0.000 claims description 41
- 108020004707 nucleic acids Proteins 0.000 claims description 41
- 238000003776 cleavage reaction Methods 0.000 claims description 39
- 230000007017 scission Effects 0.000 claims description 39
- 239000013598 vector Substances 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 230000006801 homologous recombination Effects 0.000 claims description 25
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 23
- 239000013600 plasmid vector Substances 0.000 claims description 8
- 210000005253 yeast cell Anatomy 0.000 claims description 6
- 238000001890 transfection Methods 0.000 claims description 5
- 230000001131 transforming effect Effects 0.000 claims description 4
- 108700008625 Reporter Genes Proteins 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 description 21
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 21
- 108090000790 Enzymes Proteins 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- 241000235648 Pichia Species 0.000 description 3
- 102000013009 Pyruvate Kinase Human genes 0.000 description 3
- 108020005115 Pyruvate Kinase Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222128 Candida maltosa Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150038242 GAL10 gene Proteins 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235650 Kluyveromyces marxianus Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102100037214 Orotidine 5'-phosphate decarboxylase Human genes 0.000 description 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- -1 Pho5 Chemical compound 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- NRAUADCLPJTGSF-ZPGVOIKOSA-N [(2r,3s,4r,5r,6r)-6-[[(3as,7r,7as)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo[4,5-c]pyridin-2-yl]amino]-5-[[(3s)-3,6-diaminohexanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl] carbamate Chemical compound NCCC[C@H](N)CC(=O)N[C@@H]1[C@@H](O)[C@H](OC(N)=O)[C@@H](CO)O[C@H]1\N=C/1N[C@H](C(=O)NC[C@H]2O)[C@@H]2N\1 NRAUADCLPJTGSF-ZPGVOIKOSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000009394 selective breeding Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
Definitions
- the invention relates to compositions and methods for improving plasmid transformation efficiency. Specifically, the invention relates to a linear plasmid transformation and a self- homologous recombination. The invention further relates to a combination of a selectable marker having a start codon and its homologous selectable marker lacking a start codon, in a plasmid, and uses thereof, for improving plasmid transformation efficiency.
- An expression/cloning vector otherwise known as an expression/cloning construct, is usually a plasmid designed for protein expression, cloning or manipulation in cells.
- the vector is used to introduce a specific gene into a target cell, and can commandeer the cell's mechanism for protein synthesis to produce the protein encoded by the gene.
- Expression vectors are the basic tools in biotechnology for the production of proteins.
- the plasmid is engineered to contain regulatory sequences that act as enhancer and promoter regions and lead to efficient transcription of the gene carried on the expression vector. The goal of a well-designed expression vector is the efficient production of protein.
- Yeast cells offer many of the advantages of producing proteins in microbes (e.g., growth speed, easy genetic manipulation, low cost media) while offering some of the attributes of higher eukaryotic systems (e.g., post translational modifications, secretory expression).
- yeast protein expression systems exist in organisms from the genera Saccharomyces, Pichia, Kluyveromyces, Hansenula and Yarrowia.
- Yeast plasmid transformation is a common molecular genetic manipulation by which an exogenous DNA is being delivered into the yeast cell.
- homologous recombination in yeast have been exploited to generate large DNA libraries (>10 8 ) by transforming a linearized plasmid backbone with library DNA inserts that are homologously recombined to form autonomous replicating circular plasmids. It has been shown that homologous recombination leads to DNA shuffling between DNA inserts sharing high homology generating chimeric inserts which may lead to alternate representation of DNA libraries upon transformation. While transformation of circular plasmids lowers DNA shuffling events, it suffers from lower transformation efficiency.
- the invention provides a recombinant nucleic acid molecule comprising: a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3 ' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5 ' end.
- the invention provides a vector comprising the recombinant nucleic acid molecule.
- the vector is a plasmid vector, for example, a yeast plasmid vector.
- the invention provides a method for transforming a gene of interest to a host cell, the method comprising: providing a vector comprising a recombinant nucleic acid molecule, said molecule comprising a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of recombining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5' end; providing one or more restriction enzymes capable of cleaving said restriction enzyme cleavage site of said first nucleic acid sequence and said restriction enzyme cleavage site of said second nucleic acid sequence;
- the invention provides a method for enhancing a transformation efficiency, the method comprising: providing a vector comprising a recombinant nucleic acid molecule, said molecule comprising a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5' end; providing one or more restriction enzymes capable of cleaving said restriction enzyme cleavage site of said first nucleic acid sequence and said restriction enzyme cleavage site of said second nucleic acid sequence; facilitating a transformation of the cleaved nucleic acid sequence into said host cell; and facilitating a homologous recombination
- the invention provides a kit comprising a recombinant nucleic acid molecule, said molecule comprising: a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5 ' end.
- Figure 1 shows a schematic detailing the self-recombination cloning strategy.
- the circular plasmid is digested in the selectable marker and forms a linear dsDNA plasmids.
- the plasmid is delivered into the yeast cell and re-circularized forming a plasmid that can be selected by it's full framed selectable marker.
- the invention provides compositions and methods for linear plasmid transformation by self- homologous recombination. Specifically, the invention provides a combination of a selectable marker having a start codon and its homologous selectable marker lacking a start codon in a plasmid, and uses thereof, for improving plasmid transformation efficiency.
- the inventors of this application have developed a new plasmid transformation strategy in which a linearized plasmid with two homology regions is being transformed and re- circularized by self- homologous recombination, forming a full- framed selectable marker.
- a recombinant nucleic acid molecule comprising: a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination.
- the first nucleic acid sequence may include a restriction enzyme cleavage site at its 3 ' end and the second nucleic acid sequence may include a restriction enzyme cleavage site at its 5 ' end.
- restriction enzyme cleavage site known to one of skilled in the art can be used.
- restriction enzyme for cleavage include, for example, but not limited to, type I, II, III, IV, V, and artificial restriction enzymes.
- Type I enzymes are complex, multisubunit, combination restriction-and-modification enzymes that cut DNA at random far from their recognition sequences.
- Type II enzymes cut DNA at defined positions close to or within their recognition sequences.
- One of the most common Type II enzymes, referred to as "Type IIS" are those that cleave outside of their recognition sequence to one side.
- Type III enzymes cleave outside of their recognition sequences and require two sequences in opposite orientations within the same DNA molecule to accomplish cleavage.
- Type IV enzymes recognize modified, typically methylated DNA.
- Type V restriction enzymes utilize guide RNAs to target specific non-palindromic sequences found on invading organisms. Artificial restriction enzymes are well known in the art. Artificial restriction enzymes can be engineered to bind to desired DNA sequences.
- the restriction enzyme of the invention is a type II restriction enzyme, for example, a type lis restriction endo nuclease, such as Bsal, known to one of skilled in the art.
- Type lis enzymes cut outside of their recognition site; the restriction sites in the plasmid are eliminated by the digestion and that way the marker recombination sites are 100% homologous.
- Restriction sites and enzymes for yeast plasmid vectors are well known in the art. See e.g., Ma et al, 1987, Gene, vol. 58, pages 201-216.
- restriction enzymes include, for example, but are not limited to, Aatl, Aval, BamHl, Ball, BstEI, BssHll, Bsml, BSPMI, BstXI, Cla ⁇ , DralW, Spel, Sphl, Bglll, Hindlll, Nrul, Kpnl, Bell, Smal, Mstll, Ncol, Ndel, Nhel, Xhol, Pstl, Pvull, Hpal, EcoRl, Sail, Seal, SnaBl, Sspl, Stul, Styl, Tthl, Pvul, BspMll, ⁇ ⁇ , Xbal, Apal, and Xmalll.
- selectable marker any suitable selectable marker, known to one of skilled in the art can be used.
- selectable marker may refer to a gene introduced into a cell that confers a trait suitable for artificial selection.
- the selectable marker is a type of reporter gene used in laboratory microbiology, molecular biology, and genetic engineering to indicate the success of a transfection or other procedure meant to introduce foreign nucleic acid into a cell.
- the selectable marker is a positive selectable marker.
- Positive selection marker may confer selective advantage to the host organism.
- the positive selectable marker is an antibiotic resistant gene, which allows the host organism to survive antibiotic selection. The host cells that have been subjected to a procedure to introduce foreign DNA are grown on a medium containing an antibiotic, and those colonies that can grow have successfully taken up and expressed the introduced genetic material.
- the positive selectable marker may confer resistance to antibiotics such as, for example, zeocin, geneticin, nourseothricin.
- the selectable marker is a gene that encodes an enzyme that can complement an auxotrophy, for example a TRP marker In the lab i actually do this using TRP marker that can synthesize tryptophan and grow on media that lacks it.
- the selectable marker is a negative selectable marker.
- Negative or counterselectable markers are selectable markers that eliminate or inhibit growth of the host organism upon selection.
- An example of a negative selectable marker includes thymidine kinase, which makes a host sensitive to ganciclovir selection.
- the selectable marker is a combination of a positive and a negative selectable marker. Such a marker can serve as both a positive and a negative marker by conferring an advantage to the host under one condition, but inhibits growth under a different condition.
- the combination of positive and negative selectable marker includes an enzyme that can complement an auxotrophy (positive selection) and be able to convert a chemical to a toxic compound (negative selection).
- selectable markers include, but are not limited to, ⁇ -lactamase which confers ampicillin resistance to bacterial hosts; neo gene from Tn5, which confers resistance to kanamycin and geneticin; and mutant FabI gene (mFabl), which confers triclosan resistance to the host.
- the selectable marker is a yeast marker, for example, URA3, an orotidine-5' phosphate decarboxylase from yeast, which is a positive and negative selectable marker.
- the nucleic acid sequence of a selectable marker may be of any suitable length. In a particular embodiment, the length of said selectable marker nucleic acid sequence ranges from approximately 20 bp to approximately 100 bp.
- the selectable marker comprises a start codon. In another embodiment, the selectable marker lacks a start codon. In yet another embodiment, the invention relates to a combination of a start codon containing selectable marker and its homologous start codon lacking selectable marker, wherein the start codon lacking selectable marker is capable of combiding with the start codon containing selectable marker by homologous recombination.
- the invention provides a vector comprising a start codon containing selectable marker fused or operably linked to its homologous start codon lacking selectable marker by a linker.
- the linker may comprise one or more cleavable restriction sites discussed herein.
- the start codon is a standard AUG (or ATG) codon, found in both prokaryotes and eukaryotes.
- the start codon is a non-AUG (or non-ATG) codon. Alternate start codons (non AUG) are very rare in eukaryotic genomes. However, naturally occurring non-AUG start codons have been reported for some cellular mRNAs. See Ivanov et al, 2011 , Nucleic Acids Research vol. 39 (10), pages 4220-4234.
- the selectable marker or any gene of interest in the invention may also comprise a stop codon.
- a stop codon (or termination codon) may refer to a nucleotide triplet within messenger RNA that signals a termination of translation. Examples of stop codon include, for example, but not limited to UAG, UAA, and UGA.
- the invention also includes a recombinant vector comprising any of the nucleic acid molecules described herein.
- Vector can be any suitable vector known to one of skilled in the art.
- the vector is a plasmid vector.
- plasmid as used herein may refer to a small DNA molecule within a cell that is physically separated from a chromosomal DNA and can replicate independently. Plasmids are considered replicons, a unit of DNA capable of replicating autonomously within a suitable host.
- the plasmid is a yeast plasmid.
- Yeast is organism that naturally harbour plasmids. Both circular and linear plasmids are encompassed within the scope of the invention.
- the gene URA3 that codes an enzyme related to the biosynthesis of pyrimidine nucleotides (T, C).
- the plasmid is a Yeast Replicative Plasmid (YRp).
- YRp transports a sequence of chromosomal DNA that includes an origin of replication.
- Other suitable vecotors are also within the scope of the invention.
- Other exemplary vectors include, but are not limited to, phagemids, cosmids, and phage nucleic acids or other nucleic acid molecules that are capable of replication in a prokaryotic or eukaryotic host.
- the vector is an expression vector, wherein the nucleic acid encoding an antibody is operably linked to an expression control sequence.
- Typical expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the nucleic acid molecules of the invention.
- the vectors may also contain genetic expression cassettes containing an independent terminator sequence, sequences permitting replication of the vector, or other elements known to one of skill in the art.
- the nucleic acid encoding the heavy chain may be under the same or a separate promoter.
- the separate promoters may be identical or may be different types of promoters.
- Suitable promoters include constitutive promoters and inducible promoters.
- Representative expression control sequences/promoters include, for example, the glycolytic promoters of yeast, e.g. , the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, e.g., Pho5, the promoters of the yeast alpha mating factors, the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of fd coat protein, promoters derived from the human cytomegalovirus, metallothionine promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter and promoters derived from polyoma, adenovirus, retrovirus, and simian virus, e.g., the early and late promoters of SV40.
- promoters useful in yeast expression systems include, for example, promoters from sequences encoding enzymes in the metabolic pathway such as alcohol dehydrogenase (ADH) (EPO Publication No. 284,044), enolase, glucokinase, glucose-6- phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO Publication No. 329,203) promoters.
- the expression construct comprises a synthetic hybrid promoter.
- hybrid promoters examples include the ADH regulatory sequence linked to the GAP transcription activation region (U.S. Pat. Nos. 4,876,197 and 4,880,734), as well as promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, or PH05 genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK (EPO Publication No. 164,556).
- promoters can be obtained from commercially available plasmids, using techniques well known in the art.
- transcription termination and polyadenylation sequences are also present in the expression constructs. These sequences are located 3' to the translation stop codon for the coding sequence. Transcription terminator/polyadenylation signal sequences are well known in the art.
- a host of the present invention may be eukaryotic or prokaryotic.
- Suitable eukaryotic cells include yeast and other fungi, insect cells, plant cells, human cells, and animal cells, including mammalian cells, such as hybridoma lines, COS cells, NS0 cells and CHO cells.
- Suitable prokaryotic hosts include, for example, E. coli, such as E. coli SG-936, E. coli HB 101, E. coli W3110, E. coli X1776, E. coli X2282, E. coli DHI, and E. coli MRC1 , Pseudomonas, Bacillus, such as Bacillus subtilis, and Streptomyces.
- the term "host cell”, as used herein, refers to a cell or population of cells into which a nucleic acid molecule or vector of the invention is introduced.
- a population of host cells refers to a group of cultured cells into which a nucleic acid molecule or vector of the present invention can be introduced and expressed.
- the host may contain a nucleic acid or vector encoding only one chain or portion thereof (e.g. , the heavy or light chain); or it may contain a nucleic acid or vector encoding both chains or portions thereof, either the same or separate nucleic acids and/or vectors.
- Nucleic acid molecules comprising nucleotide sequences of interest can be stably integrated into a host cell genome or maintained on a stable episomal element in a suitable host cell using various gene delivery techniques well known in the art. See, e.g., U.S. Pat. No. 5,399,346. A number of appropriate host cells for use with the above systems are also known.
- yeast hosts useful in the present invention include, but not limited to, Saccharomyces cerevisiae, Candida albicans, Candida maltosa, Hansenula polymorpha, Kluyveromyces fragilis, Kluyveromyces lactis, Pichia guillerimondii, Pichia pastoris, Schizosaccharomyces pombe and Yarrowia lipolytica.
- bacterial hosts such as E. coli, Bacillus subtilis, and Streptococcus spp., may find use with the present expression constructs.
- Insect cells for use with baculovirus expression vectors include, but not limited to, Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, and Spodoptera frugiperda.
- Mammalian cell lines are known in the art and include immortalized cell lines available from the American Type Culture Collection (ATCC), such as, but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human embryonic kidney cells, human hepatocellular carcinoma cells (e.g., Hep G2), Madin-Darby bovine kidney (“MDBK”) cells, as well as others.
- ATCC American Type Culture Collection
- the present invention can be used in expression constructs to express a wide variety of substances.
- AJ gene of interest can be expressed.
- the present invention is used to express an antibody, for example, a monoclonal antibody, a polyclonal antibody, a humanized recombinant, or a fragment thereof.
- the invention is used to express the nucleic acid sequence that encodes a heavy or light chain immunoglobulin.
- a vector of the invention can be constructed by methods or techniques well known in the art.
- Construction of yeast strains are well known and fully disclosed, for example, in U.S. Patent 5,635,369 and U.S. Patent Application Publication 2002/0160380, which are incorporated by reference herein in their entirety. Plasmid construction by homologous recombination yeast is also known in the art. See e.g., Ma et al, 1987, Gene, vol. 58, pages 201-216, which is incorporated by reference herein in its entirety.
- a wide variety of methods known to one of skilled in the art, can be used to deliver the expression constructs to cells.
- Such methods include, for example, but are not limited to, lithium acetate transformation, DEAE dextran-mediated transfection, calcium phosphate precipitation, polylysine- or polyomithine-mediated transfection, electroporation, sonoporation, protoplast fusion, liposomes, peptoid delivery, or microinjection.
- a method for transforming a gene of interest to a host cell comprising: providing a vector comprising a recombinant nucleic acid molecule, said molecule comprising a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5' end; providing one or more restriction enzymes capable of cleaving said restriction enzyme cleavage site of said first nucleic acid sequence and said restriction enzyme cleavage site of said second nucleic acid sequence; facilitating a transformation of the cleaved nucleic acid sequence into said host cell; facilitating a homologous
- the invention also provides a kit comprising a recombinant nucleic acid molecule, said molecule comprising: a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5' end.
- kits for contracting vectors of or performing assays are provided by the present invention.
- the kits can include a container that includes some or all of the reagents and methods for contracting vectors or carrying out the assays.
- the kits can also include labels or instructions for contracting vectors or carrying out the assays.
- nucleic acid may include both double- and single-stranded sequences and refers to, but not limited to, cDNA from yeast, procaryotic or eucaryotic mRNA, genomic DNA sequences, or procaryotic DNA, and especially synthetic DNA sequences. The term also captures sequences that include any of the known base analogs of DNA and RNA.
- operably linked refers to an arrangement of elements wherein the components so described are configured so as to perform their desired function.
- nucleic acid molecule means a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation is not associated with all or a portion of the polynucleotide with which it is associated in nature.
- recombinant as used with respect to a protein or polypeptide means a polypeptide produced by expression of a recombinant polynucleotide.
- the gene of interest is cloned and then expressed in transformed organisms, as described further below. The host organism expresses the foreign gene to produce the protein under expression conditions.
- promoter refers to a DNA regulatory region capable of binding RNA polymerase in a host cell and initiating transcription of a downstream (3' direction) coding sequence operably linked thereto.
- a promoter sequence includes the minimum number of bases or elements necessary to initiate transcription of a gene of interest at levels detectable above background.
- a transcription initiation site within the promoter sequence is a transcription initiation site, as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.
- host cell refers to a cell which has been transformed, or is capable of transformation, by an exogenous DNA sequence.
- expression construct refers to an assembly which is capable of directing the expression of the sequence(s) or gene(s) of interest.
- the expression construct includes control elements, as described above, such as a promoter or promoter/enhancer which is operably linked to (so as to direct transcription of) the sequence(s) or gene(s) of interest, and often includes a polyadenylation sequence as well.
- the expression construct described herein may be contained within a plasmid construct.
- the plasmid construct may also include, one or more selectable markers, a signal which allows the plasmid construct to exist as single- stranded DNA (e.g., an origin of replication).
- Our invention presents a new plasmid transformation strategy in which a linearized plasmid with two homology regions is being transformed and re-circularized by self-homologous recombination, forming a full- framed selectable marker.
- Our invention utilizes yeast homologous recombinations machinery for the transformation of linear autonomous replicating plasmid and it's re-circularization by specific self-recombination site located within the plasmid selective marker open reading frame.
- the selective marker self-recombination cassette construct contain the initial 100 bp of the selective gene, following by a stop-codon and two inverted type lis restriction site and the entire selective marker lacking an initiation ATG codon.
- FIG. 1 shows a schematic detailing the self-recombination cloning strategy. As shown in Figure 1 , the circular plasmid is digested in the selectable marker and forms a linear dsDNA plasmids. The plasmid is delivered into the yeast cell and re-circulized forming a plasmid that can be selected by it's full framed selectable marker.
- the invention offers an improved transformation efficiency than the conventional circular plasmid, while preventing notorious DNA shuffling between DNA constructs.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to compositions and methods for improving a plasmid transformation. Specifically, the invention relates to a linear plasmid transformation and a self-homologous recombination. The invention further relates to a combination of a selectable marker having a start codon and its homologous selectable marker lacking a start codon, and uses thereof, for improving a plasmid transformation.
Description
COMPOSITIONS AND METHODS FOR SELF-RECOMBINATION PLASMID
TRANSFORMATION
FIELD OF THE INVENTION
[0001] The invention relates to compositions and methods for improving plasmid transformation efficiency. Specifically, the invention relates to a linear plasmid transformation and a self- homologous recombination. The invention further relates to a combination of a selectable marker having a start codon and its homologous selectable marker lacking a start codon, in a plasmid, and uses thereof, for improving plasmid transformation efficiency.
BACKGROUND OF THE INVENTION
[0002] An expression/cloning vector, otherwise known as an expression/cloning construct, is usually a plasmid designed for protein expression, cloning or manipulation in cells. The vector is used to introduce a specific gene into a target cell, and can commandeer the cell's mechanism for protein synthesis to produce the protein encoded by the gene. Expression vectors are the basic tools in biotechnology for the production of proteins. [0003] The plasmid is engineered to contain regulatory sequences that act as enhancer and promoter regions and lead to efficient transcription of the gene carried on the expression vector. The goal of a well-designed expression vector is the efficient production of protein.
[0004] Different organisms may be used to express a target protein. The expression vector used therefore will have elements specific for use in the particular organism. [0005] Yeast cells offer many of the advantages of producing proteins in microbes (e.g., growth speed, easy genetic manipulation, low cost media) while offering some of the attributes of higher eukaryotic systems (e.g., post translational modifications, secretory expression). Several yeast protein expression systems exist in organisms from the genera Saccharomyces, Pichia, Kluyveromyces, Hansenula and Yarrowia. [0006] Yeast plasmid transformation is a common molecular genetic manipulation by which an exogenous DNA is being delivered into the yeast cell.
[0007] Homologous recombination in yeast have been exploited to generate large DNA libraries (>108) by transforming a linearized plasmid backbone with library DNA inserts that are homologously recombined to form autonomous replicating circular plasmids. It has been shown that homologous recombination leads to DNA shuffling between DNA inserts sharing high homology generating chimeric inserts which may lead to alternate representation of DNA libraries upon transformation. While transformation of circular plasmids lowers DNA shuffling events, it suffers from lower transformation efficiency.
[0008] Accordingly, there exists a need for improved systems and method for plasmid transformation. SUMMARY OF THE INVENTION
[0009] In one aspect, the invention provides a recombinant nucleic acid molecule comprising: a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3 ' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5 ' end. In one example, the invention provides a vector comprising the recombinant nucleic acid molecule. In an exemplary embodiment, the vector is a plasmid vector, for example, a yeast plasmid vector. [00010] In another aspect, the invention provides a method for transforming a gene of interest to a host cell, the method comprising: providing a vector comprising a recombinant nucleic acid molecule, said molecule comprising a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of recombining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5' end; providing one or more restriction enzymes capable of cleaving said restriction enzyme cleavage site of said first nucleic acid sequence and said restriction enzyme cleavage site of said second nucleic acid sequence; facilitating a transformation of the cleaved nucleic acid sequence into said host cell; and facilitating a
homologous recombination between said first and second nucleic acid sequences in order to form a circular plasmid in said cell with an operational selection marker .
[00011] In yet another aspect, the invention provides a method for enhancing a transformation efficiency, the method comprising: providing a vector comprising a recombinant nucleic acid molecule, said molecule comprising a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5' end; providing one or more restriction enzymes capable of cleaving said restriction enzyme cleavage site of said first nucleic acid sequence and said restriction enzyme cleavage site of said second nucleic acid sequence; facilitating a transformation of the cleaved nucleic acid sequence into said host cell; and facilitating a homologous recombination between said first and second nucleic acid sequences in order to form a circular plasmid in said cell.
[00012] In a further aspect, the invention provides a kit comprising a recombinant nucleic acid molecule, said molecule comprising: a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5 ' end.
[00013] Other features and advantages of the present invention will become apparent from the following detailed description examples and figures. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[00014] The invention will be better understood from a reading of the following detailed description taken in conjunction with the drawings:
[00015] Figure 1 shows a schematic detailing the self-recombination cloning strategy. The circular plasmid is digested in the selectable marker and forms a linear dsDNA plasmids. By homologous recombination, the plasmid is delivered into the yeast cell and re-circularized forming a plasmid that can be selected by it's full framed selectable marker.
DETAILED DESCRIPTION OF THE INVENTION
[00016] The invention provides compositions and methods for linear plasmid transformation by self- homologous recombination. Specifically, the invention provides a combination of a selectable marker having a start codon and its homologous selectable marker lacking a start codon in a plasmid, and uses thereof, for improving plasmid transformation efficiency.
[00017] The inventors of this application have developed a new plasmid transformation strategy in which a linearized plasmid with two homology regions is being transformed and re- circularized by self- homologous recombination, forming a full- framed selectable marker.
[00018] In one aspect, provided herein is a recombinant nucleic acid molecule comprising: a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination. [00019] The first nucleic acid sequence may include a restriction enzyme cleavage site at its 3 ' end and the second nucleic acid sequence may include a restriction enzyme cleavage site at its 5 ' end.
[00020] Any suitable restriction enzyme cleavage site known to one of skilled in the art can be used. Examples of restriction enzyme for cleavage include, for example, but not limited to, type I, II, III, IV, V, and artificial restriction enzymes.
[00021] Type I enzymes are complex, multisubunit, combination restriction-and-modification enzymes that cut DNA at random far from their recognition sequences. Type II enzymes cut DNA at defined positions close to or within their recognition sequences. One of the most
common Type II enzymes, referred to as "Type IIS" are those that cleave outside of their recognition sequence to one side.
[00022] Type III enzymes cleave outside of their recognition sequences and require two sequences in opposite orientations within the same DNA molecule to accomplish cleavage. Type IV enzymes recognize modified, typically methylated DNA. Type V restriction enzymes utilize guide RNAs to target specific non-palindromic sequences found on invading organisms. Artificial restriction enzymes are well known in the art. Artificial restriction enzymes can be engineered to bind to desired DNA sequences.
[00023] In a particular embodiment, the restriction enzyme of the invention is a type II restriction enzyme, for example, a type lis restriction endo nuclease, such as Bsal, known to one of skilled in the art. Type lis enzymes cut outside of their recognition site; the restriction sites in the plasmid are eliminated by the digestion and that way the marker recombination sites are 100% homologous.
[00024] Restriction sites and enzymes for yeast plasmid vectors are well known in the art. See e.g., Ma et al, 1987, Gene, vol. 58, pages 201-216. Examples of restriction enzymes include, for example, but are not limited to, Aatl, Aval, BamHl, Ball, BstEI, BssHll, Bsml, BSPMI, BstXI, Cla\, DralW, Spel, Sphl, Bglll, Hindlll, Nrul, Kpnl, Bell, Smal, Mstll, Ncol, Ndel, Nhel, Xhol, Pstl, Pvull, Hpal, EcoRl, Sail, Seal, SnaBl, Sspl, Stul, Styl, Tthl, Pvul, BspMll, Αν ΙΙΙ, Xbal, Apal, and Xmalll. [00025] With respect to the selectable marker, any suitable selectable marker, known to one of skilled in the art can be used. The term "selectable marker," as used herein, may refer to a gene introduced into a cell that confers a trait suitable for artificial selection. In one example, the selectable marker is a type of reporter gene used in laboratory microbiology, molecular biology, and genetic engineering to indicate the success of a transfection or other procedure meant to introduce foreign nucleic acid into a cell.
[00026] In one embodiment, the selectable marker is a positive selectable marker. Positive selection marker may confer selective advantage to the host organism. In one example, the positive selectable marker is an antibiotic resistant gene, which allows the host organism to survive antibiotic selection. The host cells that have been subjected to a procedure to introduce foreign DNA are grown on a medium containing an antibiotic, and those colonies that can grow
have successfully taken up and expressed the introduced genetic material. In one embodiment, the positive selectable marker may confer resistance to antibiotics such as, for example, zeocin, geneticin, nourseothricin. In one embodiment, the selectable marker is a gene that encodes an enzyme that can complement an auxotrophy, for example a TRP marker In the lab i actually do this using TRP marker that can synthesize tryptophan and grow on media that lacks it.
[00027] In another embodiment, the selectable marker is a negative selectable marker. Negative or counterselectable markers are selectable markers that eliminate or inhibit growth of the host organism upon selection. An example of a negative selectable marker includes thymidine kinase, which makes a host sensitive to ganciclovir selection. [00028] In yet another embodiment, the selectable marker is a combination of a positive and a negative selectable marker. Such a marker can serve as both a positive and a negative marker by conferring an advantage to the host under one condition, but inhibits growth under a different condition. In one example, the combination of positive and negative selectable marker includes an enzyme that can complement an auxotrophy (positive selection) and be able to convert a chemical to a toxic compound (negative selection).
[00029] Additional examples of selectable markers include, but are not limited to, β-lactamase which confers ampicillin resistance to bacterial hosts; neo gene from Tn5, which confers resistance to kanamycin and geneticin; and mutant FabI gene (mFabl), which confers triclosan resistance to the host. [00030] In a particular embodiment, the selectable marker is a yeast marker, for example, URA3, an orotidine-5' phosphate decarboxylase from yeast, which is a positive and negative selectable marker.
[00031] Useful markers for other expression systems are well known to those of skill in the art. These and other selectable markers can be obtained from commercially available plasmids, using techniques well known in the art.
[00032] The nucleic acid sequence of a selectable marker may be of any suitable length. In a particular embodiment, the length of said selectable marker nucleic acid sequence ranges from approximately 20 bp to approximately 100 bp.
[00033] In one embodiment, the selectable marker comprises a start codon. In another embodiment, the selectable marker lacks a start codon. In yet another embodiment, the invention relates to a combination of a start codon containing selectable marker and its homologous start codon lacking selectable marker, wherein the start codon lacking selectable marker is capable of combiding with the start codon containing selectable marker by homologous recombination. In one example, the invention provides a vector comprising a start codon containing selectable marker fused or operably linked to its homologous start codon lacking selectable marker by a linker. The linker may comprise one or more cleavable restriction sites discussed herein.
[00034] In one example, the start codon is a standard AUG (or ATG) codon, found in both prokaryotes and eukaryotes. In another example, the start codon is a non-AUG (or non-ATG) codon. Alternate start codons (non AUG) are very rare in eukaryotic genomes. However, naturally occurring non-AUG start codons have been reported for some cellular mRNAs. See Ivanov et al, 2011 , Nucleic Acids Research vol. 39 (10), pages 4220-4234.
[00035] The selectable marker or any gene of interest in the invention may also comprise a stop codon. In the genetic code, a stop codon (or termination codon) may refer to a nucleotide triplet within messenger RNA that signals a termination of translation. Examples of stop codon include, for example, but not limited to UAG, UAA, and UGA.
[00036] The invention also includes a recombinant vector comprising any of the nucleic acid molecules described herein. Vector can be any suitable vector known to one of skilled in the art. In a particular embodiment, the vector is a plasmid vector. The term "plasmid," as used herein may refer to a small DNA molecule within a cell that is physically separated from a chromosomal DNA and can replicate independently. Plasmids are considered replicons, a unit of DNA capable of replicating autonomously within a suitable host.
[00037] In one example, the plasmid is a yeast plasmid. Yeast is organism that naturally harbour plasmids. Both circular and linear plasmids are encompassed within the scope of the invention. For example, the gene URA3, that codes an enzyme related to the biosynthesis of pyrimidine nucleotides (T, C).
[00038] In another embodiment, the plasmid is a Yeast Replicative Plasmid (YRp). In some embodiments, YRp transports a sequence of chromosomal DNA that includes an origin of replication.
[00039] Other suitable vecotors are also within the scope of the invention. Other exemplary vectors include, but are not limited to, phagemids, cosmids, and phage nucleic acids or other nucleic acid molecules that are capable of replication in a prokaryotic or eukaryotic host.
[00040] In one embodiment, the vector is an expression vector, wherein the nucleic acid encoding an antibody is operably linked to an expression control sequence. Typical expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the nucleic acid molecules of the invention. The vectors may also contain genetic expression cassettes containing an independent terminator sequence, sequences permitting replication of the vector, or other elements known to one of skill in the art. When the vector contains nucleic acids encoding both a heavy and light chain or portions thereof, the nucleic acid encoding the heavy chain may be under the same or a separate promoter. The separate promoters may be identical or may be different types of promoters.
[00041] Suitable promoters include constitutive promoters and inducible promoters. Representative expression control sequences/promoters include, for example, the glycolytic promoters of yeast, e.g. , the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, e.g., Pho5, the promoters of the yeast alpha mating factors, the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of fd coat protein, promoters derived from the human cytomegalovirus, metallothionine promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter and promoters derived from polyoma, adenovirus, retrovirus, and simian virus, e.g., the early and late promoters of SV40.
[00042] In some embodiments, promoters useful in yeast expression systems include, for example, promoters from sequences encoding enzymes in the metabolic pathway such as alcohol dehydrogenase (ADH) (EPO Publication No. 284,044), enolase, glucokinase, glucose-6- phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO Publication No. 329,203) promoters. In some embodiments, the expression construct comprises a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (U.S. Pat. Nos. 4,876,197 and 4,880,734), as well as promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, or PH05 genes, combined with the transcriptional activation region of a
glycolytic enzyme gene such as GAP or PyK (EPO Publication No. 164,556). These and other promoters can be obtained from commercially available plasmids, using techniques well known in the art.
[00043] In another embodiment, transcription termination and polyadenylation sequences are also present in the expression constructs. These sequences are located 3' to the translation stop codon for the coding sequence. Transcription terminator/polyadenylation signal sequences are well known in the art.
[00044] A host of the present invention may be eukaryotic or prokaryotic. Suitable eukaryotic cells include yeast and other fungi, insect cells, plant cells, human cells, and animal cells, including mammalian cells, such as hybridoma lines, COS cells, NS0 cells and CHO cells. Suitable prokaryotic hosts include, for example, E. coli, such as E. coli SG-936, E. coli HB 101, E. coli W3110, E. coli X1776, E. coli X2282, E. coli DHI, and E. coli MRC1 , Pseudomonas, Bacillus, such as Bacillus subtilis, and Streptomyces.
[00045] The term "host cell", as used herein, refers to a cell or population of cells into which a nucleic acid molecule or vector of the invention is introduced. "A population of host cells" refers to a group of cultured cells into which a nucleic acid molecule or vector of the present invention can be introduced and expressed. The host may contain a nucleic acid or vector encoding only one chain or portion thereof (e.g. , the heavy or light chain); or it may contain a nucleic acid or vector encoding both chains or portions thereof, either the same or separate nucleic acids and/or vectors.
[00046] Nucleic acid molecules comprising nucleotide sequences of interest can be stably integrated into a host cell genome or maintained on a stable episomal element in a suitable host cell using various gene delivery techniques well known in the art. See, e.g., U.S. Pat. No. 5,399,346. A number of appropriate host cells for use with the above systems are also known. For example, yeast hosts useful in the present invention include, but not limited to, Saccharomyces cerevisiae, Candida albicans, Candida maltosa, Hansenula polymorpha, Kluyveromyces fragilis, Kluyveromyces lactis, Pichia guillerimondii, Pichia pastoris, Schizosaccharomyces pombe and Yarrowia lipolytica. Similarly, bacterial hosts such as E. coli, Bacillus subtilis, and Streptococcus spp., may find use with the present expression constructs. Insect cells for use with baculovirus expression vectors include, but not limited to, Aedes
aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, and Spodoptera frugiperda. Mammalian cell lines are known in the art and include immortalized cell lines available from the American Type Culture Collection (ATCC), such as, but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human embryonic kidney cells, human hepatocellular carcinoma cells (e.g., Hep G2), Madin-Darby bovine kidney ("MDBK") cells, as well as others.
[00047] In another aspect, the present invention can be used in expression constructs to express a wide variety of substances. AJ gene of interest can be expressed. In an exemplary embodiment, the the present invention is used to express an antibody, for example, a monoclonal antibody, a polyclonal antibody, a humanized recombinant, or a fragment thereof. In one embodiment, the invention is used to express the nucleic acid sequence that encodes a heavy or light chain immunoglobulin.
[00048] A vector of the invention can be constructed by methods or techniques well known in the art. [00049] Construction of yeast strains are well known and fully disclosed, for example, in U.S. Patent 5,635,369 and U.S. Patent Application Publication 2002/0160380, which are incorporated by reference herein in their entirety. Plasmid construction by homologous recombination yeast is also known in the art. See e.g., Ma et al, 1987, Gene, vol. 58, pages 201-216, which is incorporated by reference herein in its entirety. [00050] A wide variety of methods, known to one of skilled in the art, can be used to deliver the expression constructs to cells. Such methods include, for example, but are not limited to, lithium acetate transformation, DEAE dextran-mediated transfection, calcium phosphate precipitation, polylysine- or polyomithine-mediated transfection, electroporation, sonoporation, protoplast fusion, liposomes, peptoid delivery, or microinjection. [00051] In another aspect, provided herein is a method for transforming a gene of interest to a host cell, the method comprising: providing a vector comprising a recombinant nucleic acid molecule, said molecule comprising a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a
restriction enzyme cleavage site at its 3' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5' end; providing one or more restriction enzymes capable of cleaving said restriction enzyme cleavage site of said first nucleic acid sequence and said restriction enzyme cleavage site of said second nucleic acid sequence; facilitating a transformation of the cleaved nucleic acid sequence into said host cell; facilitating a homologous recombination between said first and second nucleic acid sequences in order to form a circular plasmid in said cell. In yet another aspect, provided herein is a method for enhancing a transformation efficiency.
[00052] The invention also provides a kit comprising a recombinant nucleic acid molecule, said molecule comprising: a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5' end.
[00053] Kits for contracting vectors of or performing assays are provided by the present invention. The kits can include a container that includes some or all of the reagents and methods for contracting vectors or carrying out the assays. The kits can also include labels or instructions for contracting vectors or carrying out the assays. [00054] The term "nucleic acid," as used herein, may include both double- and single-stranded sequences and refers to, but not limited to, cDNA from yeast, procaryotic or eucaryotic mRNA, genomic DNA sequences, or procaryotic DNA, and especially synthetic DNA sequences. The term also captures sequences that include any of the known base analogs of DNA and RNA.
[00055] The term "operably linked," as used herein, refers to an arrangement of elements wherein the components so described are configured so as to perform their desired function.
[00056] The term "recombinant" as used herein to describe a nucleic acid molecule means a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation is not associated with all or a portion of the polynucleotide with which it is associated in nature. The term "recombinant" as used with respect to a protein or polypeptide means a polypeptide produced by expression of a recombinant polynucleotide. In general, the
gene of interest is cloned and then expressed in transformed organisms, as described further below. The host organism expresses the foreign gene to produce the protein under expression conditions.
[00057] The term "promoter," as used herein, refers to a DNA regulatory region capable of binding RNA polymerase in a host cell and initiating transcription of a downstream (3' direction) coding sequence operably linked thereto. For purposes of the present invention, a promoter sequence includes the minimum number of bases or elements necessary to initiate transcription of a gene of interest at levels detectable above background. Within the promoter sequence is a transcription initiation site, as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.
[00058] The term "host cell," as used herein, refers to a cell which has been transformed, or is capable of transformation, by an exogenous DNA sequence.
[00059] The term "expression construct," as used herein, refer to an assembly which is capable of directing the expression of the sequence(s) or gene(s) of interest. The expression construct includes control elements, as described above, such as a promoter or promoter/enhancer which is operably linked to (so as to direct transcription of) the sequence(s) or gene(s) of interest, and often includes a polyadenylation sequence as well. Within certain embodiments of the invention, the expression construct described herein may be contained within a plasmid construct. In addition to the components of the expression construct, the plasmid construct may also include, one or more selectable markers, a signal which allows the plasmid construct to exist as single- stranded DNA (e.g., an origin of replication).
[00060] All patents, patent applications, and scientific publications cited herein are hereby incorporated by reference in their entirety.
[00061] The following examples are presented in order to more fully illustrate the preferred embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.
EXAMPLES EXAMPLE 1
Linear Plasmid Transformation and Self-homologous Recombination in Yeast
[00062] Our invention presents a new plasmid transformation strategy in which a linearized plasmid with two homology regions is being transformed and re-circularized by self-homologous recombination, forming a full- framed selectable marker. [00063] Our invention utilizes yeast homologous recombinations machinery for the transformation of linear autonomous replicating plasmid and it's re-circularization by specific self-recombination site located within the plasmid selective marker open reading frame. The selective marker self-recombination cassette construct contain the initial 100 bp of the selective gene, following by a stop-codon and two inverted type lis restriction site and the entire selective marker lacking an initiation ATG codon. Lacking the initiation codon, the selective marker fail to translate and to gain any auxotrophic activity or antibiotic resistance. By plasmid linearization using the cassette type lis restriction, the linear plasmid can be self recombined utilizing the initial 100 bp of the selective marker and its homologues initiation-lacking marker, thus, circular plasmid transformation can be selected by the gain of functionality of the selection marker. [00064] Figure 1 shows a schematic detailing the self-recombination cloning strategy. As shown in Figure 1 , the circular plasmid is digested in the selectable marker and forms a linear dsDNA plasmids. The plasmid is delivered into the yeast cell and re-circulized forming a plasmid that can be selected by it's full framed selectable marker.
[00065] The invention offers an improved transformation efficiency than the conventional circular plasmid, while preventing notorious DNA shuffling between DNA constructs.
[00066] Having described preferred embodiments of the invention with reference to the accompanying drawings, it is to be understood that the invention is not limited to the precise embodiments, and that various changes and modifications may be effected therein by those skilled in the art without departing from the scope or spirit of the invention as defined in the appended claims.
Claims
1. A recombinant nucleic acid molecule comprising: a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5' end.
2. The nucleic acid molecule of claim 1, wherein said restriction enzyme cleavage site of said first nucleic acid sequence is cleavable by a type lis restriction enzyme.
3. The nucleic acid molecule of claim 2, wherein said restriction enzyme is a type lis restriction enzyme.
4. The nucleic acid molecule of claim 1, wherein said restriction enzyme cleavage site of said second nucleic acid sequence is cleavable by a type lis restriction enzyme.
5. The nucleic acid molecule of claim 4, wherein said restriction enzyme is a type lis restriction enzyme.
6. The nucleic acid molecule of claim 1, wherein said selectable marker is a reporter gene that indicates the success of a transfection or transformation to introduce a foreign nucleic acid into a cell.
7. The nucleic acid molecule of claim 1, wherein the length of said selectable marker nucleic acid sequence ranges from approximately 20 bp to approximately 100 bp.
8. The nucleic acid molecule of claim 1, wherein said start codon is AUG or ATG.
9. The nucleic acid molecule of claim 1, wherein said molecule comprises a nucleic acid sequence encoding a gene of interest.
10. The nucleic acid molecule of claim 1, wherein said molecule comprises a nucleic acid sequence encoding a self -replication gene that facilitates the self-replication of a plasmid.
11. A vector comprising said recombinant nucleic acid molecule of claim 1.
12. The vector of claim 11, wherein said vector is a plasmid vector.
13. The vector of claim 12, wherein said plasmid is a self-replicating plasmid.
14. The vector of claim 13, wherein said plasmid is a yeast plasmid.
15. An expression library comprising a vector of claim 11, 12, 13, or 14.
16. A host cell comprising a plasmid of claim 12, 13, or 14.
17. The cell of claim 16, wherein said cell is a yeast cell.
18. A method for transforming a gene of interest to a host cell, the method comprising:
providing a vector comprising a recombinant nucleic acid molecule, said molecule comprising a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3 ' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5 ' end;
providing one or more restriction enzymes capable of cleaving said restriction enzyme cleavage site of said first nucleic acid sequence and said restriction enzyme cleavage site of said second nucleic acid sequence;
facilitating a transformation of the cleaved nucleic acid sequence into said host cell; facilitating a homologous recombination between said first and second nucleic acid sequences in order to form a circular plasmid in said cell.
19. The method of claim 18, wherein said restriction enzyme cleavage site of said first nucleic acid sequence is cleavable by a type lis restriction enzyme.
20. The method of claim 19, wherein said restriction enzyme is a type II si restriction enzyme.
21. The method of claim 18, wherein said restriction enzyme cleavage site of said second nucleic acid sequence is cleavable by a type II restriction enzyme.
22. The method of claim 21, wherein said restriction enzyme is a type II si restriction enzyme.
23. The method of claim 18, wherein said selectable marker is a reporter gene that indicates the success of a transfection or transformation to introduce a foreign nucleic acid into a cell.
24. The method of claim 18, wherein the length of said selectable marker nucleic acid sequence ranges from approximately 5 bp to approximately 100 bp.
25. The method of claim 18, wherein said start codon is AUG or ATG.
26. The method of claim 18, wherein said molecule comprises a nucleic acid sequence encoding a gene of interest.
27. The method of claim 18, wherein said molecule comprises a nucleic acid sequence encoding a self-replication gene that facilitates the self-replication of a plasmid.
28. The method of claim 18, wherein said vector is a plasmid vector.
29. The method of claim 18, wherein said vector is a self-replicating plasmid vector.
30. The method of claim 18, wherein said vector is a yeast plasmid vector.
31. The method of claim 18, wherein said cell is a yeast cell.
32. A method for enhancing a transformation efficiency, the method comprising:
providing a vector comprising a recombinant nucleic acid molecule, said molecule comprising a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3 ' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5 ' end;
providing one or more restriction enzymes capable of cleaving said restriction enzyme cleavage site of said first nucleic acid sequence and said restriction enzyme cleavage site of said second nucleic acid sequence;
facilitating a transformation of the cleaved nucleic acid sequence into said host cell; facilitating a homologous recombination between said first and second nucleic acid sequences in order to form a circular plasmid in said cell.
33. A kit comprising a recombinant nucleic acid molecule, said molecule comprising: a first nucleic acid sequence of a selectable marker operably linked to a second nucleic acid sequence of said selectable marker, wherein said second nucleic acid sequence lacks a start codon and is capable of combining with said first nucleic acid sequence by homologous recombination, wherein said first nucleic acid sequence has a restriction enzyme cleavage site at its 3' end and said second nucleic acid sequence has a restriction enzyme cleavage site at its 5 ' end.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662343338P | 2016-05-31 | 2016-05-31 | |
US62/343,338 | 2016-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017210148A1 true WO2017210148A1 (en) | 2017-12-07 |
Family
ID=60477809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/034917 WO2017210148A1 (en) | 2016-05-31 | 2017-05-30 | Compositions and methods for self-recombination plasmid transformation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017210148A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111718961A (en) * | 2019-07-03 | 2020-09-29 | 华大青兰生物科技(无锡)有限公司 | Method for transforming bacteria by using plasmid |
US11127483B2 (en) | 2017-03-07 | 2021-09-21 | Igc Bio, Inc. | Computational pipeline for antibody modeling and design |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130267021A1 (en) * | 2010-06-11 | 2013-10-10 | Icon Genetics Gmbh | System and method of modular cloning |
-
2017
- 2017-05-30 WO PCT/US2017/034917 patent/WO2017210148A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130267021A1 (en) * | 2010-06-11 | 2013-10-10 | Icon Genetics Gmbh | System and method of modular cloning |
Non-Patent Citations (1)
Title |
---|
ABASTADO ET AL.: "Intramolecular recombination between partially homologous sequences in Escherichia coli and Xenopus laevis oocytes", PROC NATL ACAD SCI U S A., vol. 84, no. 18, September 1987 (1987-09-01), pages 6496 - 6500, XP055447478 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11127483B2 (en) | 2017-03-07 | 2021-09-21 | Igc Bio, Inc. | Computational pipeline for antibody modeling and design |
CN111718961A (en) * | 2019-07-03 | 2020-09-29 | 华大青兰生物科技(无锡)有限公司 | Method for transforming bacteria by using plasmid |
CN111718961B (en) * | 2019-07-03 | 2022-02-08 | 华大青兰生物科技(无锡)有限公司 | Method for transforming bacteria by using plasmid |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101903531B (en) | Yeast strains for protein production | |
EP3199632A1 (en) | Temperature-inducible crispr/cas system | |
WO2003095658A1 (en) | Homologous recombination into bacterium for the generation of polynucleotide libraries | |
US20140178933A1 (en) | Enhanced heterologous protein production in kluyveromyces marxianus | |
WO2017210148A1 (en) | Compositions and methods for self-recombination plasmid transformation | |
JP2024099583A (en) | Stable targeted integration | |
WO2016003368A1 (en) | Optimized vectors for the production of recombinant proteins | |
US20110136236A1 (en) | Genetically modified eukaryotic cells | |
US8647841B2 (en) | Artificial chromosome vector | |
CN102066563A (en) | Multi-species polynucleotide control sequences | |
JP2018504916A (en) | Method for producing a DNA vector from a molecular component containing a sequence of interest | |
JP5997140B2 (en) | Production cell line | |
KR102302827B1 (en) | Compositon for inhibiting gene expression using CRISPRi | |
LU101172B1 (en) | Method for in vivo screening of engineered enzyme variants | |
CN113677795B (en) | Novel DAHP synthetase | |
US20080227154A1 (en) | Protein Expression | |
Lin-Cereghino et al. | Expression of protein in Pichia pastoris | |
EP4130254A1 (en) | Eukaryotic cell lysates comprising exogenous enzymes and methods for preparing the same | |
JP2019088191A (en) | Inducible promoter | |
KR20220098155A (en) | Nonviral transcriptional activation domains and related methods and uses | |
WO2020055293A1 (en) | Pacas9 nuclease | |
JP2006075123A (en) | Promoter dna originated from candida utilis | |
US20050064547A1 (en) | Vectors and transfected cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17807310 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17807310 Country of ref document: EP Kind code of ref document: A1 |